What is the level of liabilities of AC Immune this year?
AC Immune has a debt balance of 22.17 M CHF this year.
AC Immune Liabilities 2024
AC Immune Liabilities
22.17 M CHF
Ticker
ACIU
ISIN
CH0329023102
WKN
A2AR5F
In 2024, AC Immune's total liabilities amounted to 22.17 M CHF, a 31.19% difference from the 16.9 M CHF total liabilities in the previous year.
AC Immune Aktienanalyse
What does AC Immune do?
AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life. AC Immune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing AC Immune's Liabilities
AC Immune's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating AC Immune's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing AC Immune's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
AC Immune's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in AC Immune’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about AC Immune stock
What were the liabilities of AC Immune compared to the previous year?
The liabilities of AC Immune have increased by 31.19% increased compared to the previous year.
What are the consequences of high debt for investors of AC Immune?
High liabilities can pose a risk for investors of AC Immune, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in AC Immune?
Low liabilities mean that AC Immune has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of AC Immune affect the company?
An increase in liabilities of AC Immune can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of AC Immune affect the company?
A decrease in the liabilities of AC Immune can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of AC Immune?
Some factors that can influence the liabilities of AC Immune include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of AC Immune so important for investors?
The liabilities of AC Immune are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can AC Immune take to modify the liabilities?
To change its liabilities, AC Immune can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does AC Immune pay?
Over the past 12 months, AC Immune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AC Immune is expected to pay a dividend of 0 CHF.
What is the dividend yield of AC Immune?
The current dividend yield of AC Immune is .
When does AC Immune pay dividends?
AC Immune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AC Immune?
AC Immune paid dividends every year for the past 0 years.
What is the dividend of AC Immune?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is AC Immune located?
AC Immune is assigned to the 'Health' sector.
Wann musste ich die Aktien von AC Immune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AC Immune from 8/18/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 8/18/2024.
When did AC Immune pay the last dividend?
The last dividend was paid out on 8/18/2024.
What was the dividend of AC Immune in the year 2023?
In the year 2023, AC Immune distributed 0 CHF as dividends.
In which currency does AC Immune pay out the dividend?
The dividends of AC Immune are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AC Immune
Our stock analysis for AC Immune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
